Assenagon Asset Management S.A. Has $2.85 Million Holdings in Chimerix, Inc. (NASDAQ:CMRX)

Assenagon Asset Management S.A. boosted its stake in shares of Chimerix, Inc. (NASDAQ:CMRX) by 154.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 817,739 shares of the biopharmaceutical company’s stock after buying an additional 496,823 shares during the period. Assenagon Asset Management S.A. owned about 0.91% of Chimerix worth $2,846,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Valeo Financial Advisors LLC increased its holdings in shares of Chimerix by 566.9% in the 3rd quarter. Valeo Financial Advisors LLC now owns 81,766 shares of the biopharmaceutical company’s stock valued at $76,000 after purchasing an additional 69,505 shares during the period. Marshall Wace LLP acquired a new position in shares of Chimerix in the 2nd quarter valued at about $137,000. Finally, Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of Chimerix by 66.8% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company’s stock valued at $321,000 after purchasing an additional 138,098 shares during the period. Institutional investors and hedge funds own 45.42% of the company’s stock.

Wall Street Analyst Weigh In

CMRX has been the topic of a number of research reports. Wedbush reiterated an “outperform” rating and issued a $6.00 target price on shares of Chimerix in a report on Tuesday, December 10th. HC Wainwright reiterated a “buy” rating and issued a $11.00 target price on shares of Chimerix in a report on Monday, December 30th.

Chimerix Stock Up 8.2 %

Shares of Chimerix stock opened at $3.84 on Wednesday. The stock has a market capitalization of $345.35 million, a P/E ratio of -4.09 and a beta of 0.36. The stock has a 50 day moving average price of $2.37 and a two-hundred day moving average price of $1.42. Chimerix, Inc. has a 12-month low of $0.75 and a 12-month high of $4.07.

Chimerix (NASDAQ:CMRX) last announced its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.02). The business had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $1.26 million. During the same period in the prior year, the firm earned ($0.27) earnings per share. Sell-side analysts anticipate that Chimerix, Inc. will post -0.99 earnings per share for the current year.

Chimerix Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.